SG11201502725TA - Heteroaromatic compounds as pi3 kinase modulators and methods of use - Google Patents
Heteroaromatic compounds as pi3 kinase modulators and methods of useInfo
- Publication number
- SG11201502725TA SG11201502725TA SG11201502725TA SG11201502725TA SG11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA SG 11201502725T A SG11201502725T A SG 11201502725TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- heteroaromatic compounds
- kinase modulators
- modulators
- kinase
- Prior art date
Links
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- 150000002390 heteroarenes Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726139P | 2012-11-14 | 2012-11-14 | |
| PCT/US2013/069366 WO2014078211A1 (fr) | 2012-11-14 | 2013-11-10 | Composés hétéroaromatiques à titre de modulateurs des pi3 kinases et leurs méthodes d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502725TA true SG11201502725TA (en) | 2015-05-28 |
Family
ID=50681898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502725TA SG11201502725TA (en) | 2012-11-14 | 2013-11-10 | Heteroaromatic compounds as pi3 kinase modulators and methods of use |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9926324B2 (fr) |
| EP (2) | EP3299019B1 (fr) |
| JP (1) | JP6268183B2 (fr) |
| KR (1) | KR102148679B1 (fr) |
| CN (1) | CN104755085B (fr) |
| AU (1) | AU2013345107B2 (fr) |
| BR (1) | BR112015006726B1 (fr) |
| CA (1) | CA2889346C (fr) |
| ES (1) | ES2661380T3 (fr) |
| HK (1) | HK1210956A1 (fr) |
| MY (1) | MY180641A (fr) |
| RU (1) | RU2665036C9 (fr) |
| SG (1) | SG11201502725TA (fr) |
| TW (1) | TWI574962B (fr) |
| WO (1) | WO2014078211A1 (fr) |
| ZA (1) | ZA201502575B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104496940B (zh) * | 2014-01-06 | 2017-03-15 | 广东东阳光药业有限公司 | 一种制备bcr‑abl抑制剂中间体的方法 |
| EP3159342B1 (fr) * | 2014-06-17 | 2020-08-05 | Cisen Pharmaceutical Co., Ltd. | Analogue de pyridino [1,2-a]pyrimidone utilisé en tant qu'inhibiteur de pi3k/mtor |
| CN105503877A (zh) | 2014-09-24 | 2016-04-20 | 和记黄埔医药（上海）有限公司 | 咪唑并哒嗪类化合物及其用途 |
| JP6568588B2 (ja) | 2014-12-19 | 2019-08-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ＰＩ３Ｋβ阻害剤としてのイミダゾピリダジン誘導体 |
| ES2760507T3 (es) | 2014-12-19 | 2020-05-14 | Janssen Pharmaceutica Nv | Derivados de imidazopiridazina enlazados a heterociclilo como inhibidores de PI3Kß |
| KR102472453B1 (ko) * | 2016-06-16 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체 |
| WO2018017633A1 (fr) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | ANTAGONISTES DU RÉCEPTEUR TGF-β |
| CN108779115B (zh) | 2016-10-14 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 |
| CN108164525B (zh) * | 2016-12-08 | 2020-09-08 | 沈阳药科大学 | 一种抗肿瘤化合物的制备方法和用途 |
| WO2018134254A1 (fr) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Inhibiteurs de protéine kinase pour favoriser la régénération du foie, ou pour réduire ou prévenir la mort des hépatocytes |
| FR3064364A1 (fr) * | 2017-03-27 | 2018-09-28 | S.P.C.M. Sa | Methode de dosage de polymeres cationiques |
| WO2023039532A1 (fr) * | 2021-09-10 | 2023-03-16 | Relay Therapeutics, Inc. | Inhibiteurs de pi3k-alpha et leurs procédés d'utilisation |
| WO2023220131A2 (fr) * | 2022-05-10 | 2023-11-16 | Relay Therapeutics, Inc. | INHIBITEURS DE PI3Kα ET LEURS PROCÉDÉS D'UTILISATION |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2036924C1 (ru) * | 1989-01-31 | 1995-06-09 | Такеда Кемикал Индастриз ЛТД | Способ получения производных имидазо (1,2-b)пиридазина или их солей и производные имидазо (1,2-b)пиридазина или их соли |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| EP0734436B1 (fr) | 1993-11-30 | 1999-04-14 | McGILL UNIVERSITY | Inhibition de la methyltransferase de l'adn |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6268137B1 (en) | 1996-05-22 | 2001-07-31 | Methylgene, Inc. | Specific inhibitors of DNA methyl transferase |
| US6020318A (en) | 1997-05-30 | 2000-02-01 | Methylgene, Inc. | DNA methyltransferase genomic sequences and antisense oligonucleotides |
| JP2002512508A (ja) | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
| US6066625A (en) | 1998-02-03 | 2000-05-23 | Methylgene, Inc. | Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
| US6953783B1 (en) | 1998-10-19 | 2005-10-11 | Methylgene, Inc. | Modulation of gene expression by combination therapy |
| JP2003500052A (ja) | 1999-05-03 | 2003-01-07 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制 |
| CA2391952C (fr) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibiteurs de l'histone deacetylase |
| JP2004533850A (ja) | 2000-03-24 | 2004-11-11 | メチルジーン・インコーポレーテッド | 特異的なヒストン脱アセチル化酵素アイソフォームの阻害 |
| WO2001070675A2 (fr) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibiteurs d'histone desacetylase |
| AU2001264595A1 (en) * | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| EP1429765A2 (fr) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibiteurs de l'histone-deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1551795A1 (fr) | 2002-10-17 | 2005-07-13 | Methylgene, Inc. | Inhibiteurs de l'histone deacetylase |
| EP1663953A1 (fr) | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibiteurs d'histone deacetylase |
| WO2005092899A1 (fr) | 2004-03-26 | 2005-10-06 | Methylgene Inc. | Inhibiteurs d'histone désacétylase |
| BRPI0513982A (pt) | 2004-07-30 | 2007-11-27 | Methylgene Inc | inibidores de sinalização de receptor de vegf e receptor de hgf |
| EP3417912B1 (fr) | 2005-12-23 | 2020-08-12 | ARIAD Pharmaceuticals, Inc. | Composants hétéroaromatiques bicycliques |
| RU2009107705A (ru) * | 2006-08-04 | 2010-09-10 | Такеда Фармасьютикал Компани Лимитед (Jp) | Конденсированное гетероциклическое соединение и его применение |
| US20100204222A1 (en) * | 2007-09-17 | 2010-08-12 | GlaxoSmithKline, LLC | Pyridopyrimidine derivatives as p13 kinase inhibitors |
| WO2009055418A1 (fr) * | 2007-10-22 | 2009-04-30 | Smithkline Beecham Corporation | Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase |
| WO2009085230A1 (fr) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibiteurs de la pi3 kinase |
| EP2265609B1 (fr) * | 2008-02-29 | 2012-09-05 | Array Biopharma, Inc. | Dérivés d'imidazo [4. 5-b] pyridine utilisés comme inhibiteurs de raf |
| WO2009133127A1 (fr) * | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Composés bicycliques fusionnés et utilisations de ceux-ci comme inhibiteurs de p13k |
| MY162604A (en) | 2009-08-17 | 2017-06-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| WO2011146882A1 (fr) * | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Composés chimiques, compositions et procédés pour modulation de kinases |
| UY33597A (es) * | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN103748099B (zh) | 2011-05-19 | 2016-08-17 | 卡洛斯三世国家癌症研究中心基金会 | 作为蛋白激酶抑制剂的大环化合物 |
| WO2012174312A2 (fr) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Dérivés de benzimidazole en tant qu'agents antiviraux |
| KR101274986B1 (ko) | 2011-07-27 | 2013-06-17 | 한국과학기술원 | 이미다조피리딘 유도체, 이를 포함하는 ＰＩ3Ｋ 및/또는 ｍＴＯＲ 저해제용 약학 조성물 및 ＰＩ3Ｋ 및/또는 ｍＴＯＲ과 연관된 질환 치료용 약학 조성물 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
-
2013
- 2013-11-08 TW TW102140742A patent/TWI574962B/zh active
- 2013-11-10 SG SG11201502725TA patent/SG11201502725TA/en unknown
- 2013-11-10 EP EP17192050.7A patent/EP3299019B1/fr active Active
- 2013-11-10 CA CA2889346A patent/CA2889346C/fr active Active
- 2013-11-10 RU RU2015116102A patent/RU2665036C9/ru active
- 2013-11-10 US US14/076,256 patent/US9926324B2/en active Active
- 2013-11-10 CN CN201380054625.XA patent/CN104755085B/zh active Active
- 2013-11-10 KR KR1020157008264A patent/KR102148679B1/ko active IP Right Grant
- 2013-11-10 MY MYPI2015701411A patent/MY180641A/en unknown
- 2013-11-10 EP EP13855522.2A patent/EP2919784B1/fr active Active
- 2013-11-10 ES ES13855522.2T patent/ES2661380T3/es active Active
- 2013-11-10 WO PCT/US2013/069366 patent/WO2014078211A1/fr active Application Filing
- 2013-11-10 AU AU2013345107A patent/AU2013345107B2/en active Active
- 2013-11-10 BR BR112015006726-3A patent/BR112015006726B1/pt not_active IP Right Cessation
- 2013-11-10 JP JP2015541973A patent/JP6268183B2/ja active Active
-
2015
- 2015-04-16 ZA ZA2015/02575A patent/ZA201502575B/en unknown
- 2015-12-02 HK HK15111830.4A patent/HK1210956A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014078211A1 (fr) | 2014-05-22 |
| RU2665036C2 (ru) | 2018-08-27 |
| BR112015006726B1 (pt) | 2021-11-23 |
| EP2919784A1 (fr) | 2015-09-23 |
| TW201422615A (zh) | 2014-06-16 |
| JP2015536994A (ja) | 2015-12-24 |
| KR102148679B1 (ko) | 2020-08-27 |
| KR20150083833A (ko) | 2015-07-20 |
| BR112015006726A2 (pt) | 2017-08-22 |
| AU2013345107B2 (en) | 2016-02-25 |
| HK1210956A1 (en) | 2016-05-13 |
| RU2015116102A (ru) | 2017-01-10 |
| RU2665036C9 (ru) | 2018-11-12 |
| TWI574962B (zh) | 2017-03-21 |
| CA2889346C (fr) | 2018-09-25 |
| JP6268183B2 (ja) | 2018-01-24 |
| ZA201502575B (en) | 2016-11-30 |
| EP3299019B1 (fr) | 2019-10-09 |
| MY180641A (en) | 2020-12-04 |
| EP2919784B1 (fr) | 2017-12-20 |
| EP2919784A4 (fr) | 2016-07-06 |
| ES2661380T3 (es) | 2018-03-28 |
| CA2889346A1 (fr) | 2014-05-22 |
| CN104755085B (zh) | 2018-05-01 |
| EP3299019A1 (fr) | 2018-03-28 |
| AU2013345107A1 (en) | 2015-04-30 |
| US20140134133A1 (en) | 2014-05-15 |
| US9926324B2 (en) | 2018-03-27 |
| CN104755085A (zh) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100049I1 (hu) | Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával | |
| IL262110A (en) | dll3 modulators and methods to use | |
| HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
| HK1210956A1 (en) | Heteroaromatic compounds as pi3 kinase modulators and methods of use pi3 | |
| HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
| EP2938341A4 (fr) | Composés hétérocycliques et leurs procédés d'utilisation | |
| HK1218385A1 (zh) | 作為 激酶調節劑的雜芳環化合物 | |
| HK1203954A1 (en) | Heteroaryl compounds and methods of use thereof | |
| HK1203494A1 (en) | Heteroaryl compounds and methods of use thereof | |
| EP2847193A4 (fr) | Composés hétéroaryles et leurs procédés d'utilisation | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors |